Metabolic & body composition
5-Amino-1MQ.
Written by the Elevate Clinical Team
Medically reviewed by Dr. Eric W. Anderson, MD · Last reviewed
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on .
A small-molecule NNMT inhibitor studied for fat-cell metabolism and NAD+ availability.
What it is
5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme elevated in obese adipose tissue. Blocking it in animal models increases intracellular NAD+ and shrinks fat cells without changing food intake. It is a small molecule, not a peptide, and it is orally available.
What it's studied for
- Adipocyte size and fat mass in rodent models
- NAD+ salvage-pathway activity
- Muscle-function research in aged animals
How it's used in practice
- Oral administration is the usual route in research settings
- Often bundled with NAD+ precursors in marketing; the mechanisms are related but not identical
What you should know before asking about it
- Research use only; not FDA-approved
- No published human trials
- NNMT has roles beyond fat tissue that inhibition may affect
Frequently asked questions.
- What is 5-Amino-1MQ?
- 5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme elevated in obese adipose tissue. Blocking it in animal models increases intracellular NAD+ and shrinks fat cells without changing food intake. It is a small molecule, not a peptide, and it is orally available.
- What is 5-Amino-1MQ studied for?
- Published and ongoing research looks at adipocyte size and fat mass in rodent models; nAD+ salvage-pathway activity; muscle-function research in aged animals. These are areas of study, not promised outcomes.
- Is 5-Amino-1MQ FDA-approved?
- 5-Amino-1MQ has not been evaluated by the FDA. Elevate Chicago lists it for education and research reference only — it is not prescribed as medical care and is not intended for human consumption.
- How is 5-Amino-1MQ typically used?
- Oral administration is the usual route in research settings. Often bundled with NAD+ precursors in marketing; the mechanisms are related but not identical. Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
- What are the risks and unknowns with 5-Amino-1MQ?
- Research use only; not FDA-approved. No published human trials. NNMT has roles beyond fat tissue that inhibition may affect.
Sources
- 1.Published literature on 5-Amino-1MQ— PubMed, U.S. National Library of Medicine
- 2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
- 3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
- 4.Test directory and patient service center locator— Quest Diagnostics
About this page
Written by the Elevate Clinical Team
Medically reviewed by Dr. Eric W. Anderson, MD · Last reviewed . Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.
This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.